FibroGen, Inc. (FGEN) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, FibroGen, Inc. (FGEN) trades at a price-to-earnings ratio of -15.6x, with a stock price of $7.50 and trailing twelve-month earnings per share of $53.33.
The current P/E is 101% below its 5-year average of 1608.7x. Over the past five years, FGEN's P/E has ranged from a low of 0.2x to a high of 2455.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, FGEN trades at a 166% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, FGEN trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our FGEN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Immunology and Inflammation Therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ARGXargenx SE | $47B | 60.0 | -Best | +348% |
TGTXTG Therapeutics, Inc. | $5B | 200.6 | -Best | +76% |
KNSAKiniksa Pharmaceuticals, Ltd. | $3B | 59.3 | -Best | +225% |
APLSApellis Pharmaceuticals, Inc. | $3B | 116.4 | -Best | +111% |
GLPGGalapagos N.V. | $2B | 5.9Lowest | -Best | +333% |
AUPHAurinia Pharmaceuticals Inc. | $2B | 6.8 | -Best | +5167%Best |
GYREGyre Therapeutics, Inc. | $711M | 164.8 | -Best | +104% |
RIGLRigel Pharmaceuticals, Inc. | $615M | 35.1 | -Best | +169% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $12.25 | $52.28 | 0.2x | -100% | |
| FY2019 Q3 | Mon Sep 30 2019 00:00:00 GM | $924.50 | $0.39 | 2370.5x | +47% |
| FY2019 Q2 | Sun Jun 30 2019 00:00:00 GM | $1129.50 | $0.46 | 2455.4x | +53% |
Average P/E for displayed period: 1608.7x
See FGEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FGEN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare FGEN vs AGIO
See how FGEN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is FGEN stock overvalued or undervalued?
FGEN trades at -15.6x P/E, below its 5-year average of 1608.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does FGEN's valuation compare to peers?
FibroGen, Inc. P/E of -15.6x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is FGEN's PEG ratio?
FGEN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2025.